There are several multiple myeloma patients who are resistant to all kinds of approved therapies. Researchers from the Tisch Cancer Institute at Mount Sinai have now reported talquetamab, a novel antibody therapy, that directs the T-cells to kill multiple myeloma cells in 73% of patients in two clinical trials. The therapy has also been successful in patients with heavily pretreated, relapsed, or multiple refractory myelomas. The drug is an off-the-shelf, humanized, T-cell redirecting bispecific antibody targeting G-protein coupled receptor family C group 5 member D (GPRC5D) and CD3 antigen.
The reported side effects were relatively frequent but mild. About 75% of patients experienced cytokine release syndrome, and about 60% experienced skin-related side effects like rash. In addition, about half reported taste changes, and half reported nail disorders. About 5-6% of patients stopped…
